<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437827</url>
  </required_header>
  <id_info>
    <org_study_id>rEEGTRD010</org_study_id>
    <secondary_id>CNSR #010</secondary_id>
    <nct_id>NCT00437827</nct_id>
  </id_info>
  <brief_title>rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure</brief_title>
  <official_title>A Multicenter, Randomized, Blinded, Controlled, Parallel Group Trial to Demonstrate the Efficacy of rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MYnd Analytics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MYnd Analytics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is testing a process (rEEG)for selecting the most appropriate medication(s) to&#xD;
      treat a patient's depression versus a control group being treated according to a standardized&#xD;
      method, the modified Star*D Algorithm. Qualified subjects will be randomized to the&#xD;
      experimental (rEEG guided) group, or the control group and treated for 12 weeks. Medications&#xD;
      utilized in this study are currently marketed. All visits, physical exam, rEEG, labs, rating&#xD;
      scales and medications are provided at no cost to the patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is testing a process (rEEG)for selecting the most appropriate medication(s) to&#xD;
      treat a patient's depression versus a control group being treated according to a standardized&#xD;
      method, the modified Star*D Algorithm. Qualified subjects will be randomized to the&#xD;
      experimental (rEEG guided) group, or the control group and treated for 10 weeks. Medications&#xD;
      utilized in this study are currently marketed. All visits, physical exam, rEEG, labs, rating&#xD;
      scales and medications are provided at no cost to the patient.&#xD;
&#xD;
      To qualify for entry into the study, patients must be:&#xD;
&#xD;
        1. 18 years of age or older.&#xD;
&#xD;
        2. Diagnosis of Major Depressive Disorder. Subjects may meet criteria for both melancholic&#xD;
           and atypical depression.&#xD;
&#xD;
        3. Have failed 1 or more SSRIs, or have failed 2 or more antidepressants in at least 2 drug&#xD;
           classes.&#xD;
&#xD;
      And patients must not have:&#xD;
&#xD;
        1. History of: closed head injury with unconsciousness, craniotomy, cerebral metastases,&#xD;
           cerebrovascular accident; no current diagnosis of seizure disorder, bipolar disorder,&#xD;
           schizophrenia, dementia, mental retardation, substance abuse, or major depression with&#xD;
           psychotic features; or use of depot neuroleptics in last 12 months.&#xD;
&#xD;
        2. Known pregnancy and/or lactation, or intent to become pregnant during this study.&#xD;
&#xD;
      Medications that can be used in this study are:&#xD;
&#xD;
      Anti-depressants: fluoxetine, sertraline, paroxetine, desipramine, imipramine,&#xD;
      nortriptyline,amitriptyline, clomipramine, bupropion, venlafaxine&#xD;
&#xD;
      Stimulants &amp; MAO Inhibitors: moclobemide, tranylcypromine, selegiline, methylphenidate,&#xD;
      dextroamphetamine, dexlevoamphetamine, pemoline, lamotrigine, topiramate&#xD;
&#xD;
      Benzodiazepines: lorazepam, clonazepam, alprazolam&#xD;
&#xD;
      Anti-convulsants: carbamazepine, lithium, divalproex, gabapentin&#xD;
&#xD;
      Beta Blockers: metoprolol, propranolol, atenolol&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Two group comparison of QIDS-SR16 and Q-LES-Q-SF</measure>
    <time_frame>after 12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Two group comparison of MADRS, Clinical Global Improvement and Severity.</measure>
    <time_frame>after 12 weeks of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each subject in this arm will receive depression therapy similar to that used by the Star*D study - a major depression study conducted in the United States (Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Am J Psychiatry 2006; 163:1905-1917)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject in this arm will receive therapy based upon an individualized rEEG report which provides one or more treatment options with the highest probability of success.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Star*D algorithm</intervention_name>
    <description>Standard of care based upon the therapies selected in the Star*D study.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Standard of Care</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>rEEG-guided therapy</intervention_name>
    <description>An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>EEG-based technology</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older.&#xD;
&#xD;
          2. Diagnosis of Major Depressive Disorder validated by SCID. Subjects may meet criteria&#xD;
             for both melancholic and atypical depression per this protocol.&#xD;
&#xD;
          3. Have failed three or more antidepressant regimens during the current depressive&#xD;
             episode with minimum daily dose(s) as defined in the Medication History for Depression&#xD;
             Case Report Form and for a minimum duration of treatment of at least 4 weeks. For&#xD;
             purposes of the Study, augmentation will be considered a separate regimen.&#xD;
&#xD;
          4. Able to stop all medications for 5 half-lives of the medication(s), with the exception&#xD;
             of hormones, thyroid, hydrochlorthiazide and Ambien. See Appendix II for a list of the&#xD;
             half-lives of medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of: closed head injury with unconsciousness, craniotomy, cerebral metastases,&#xD;
             cerebrovascular accident; no current diagnosis of seizure disorder, bipolar disorder,&#xD;
             schizophrenia, dementia, mental retardation, substance abuse, or major depression with&#xD;
             psychotic features; or use of depot neuroleptics in last 12 months.&#xD;
&#xD;
          2. Participation in any other therapeutic drug study evaluating a treatment for&#xD;
             depression within 60 days preceding inclusion, unless drug(s) half-life is known.&#xD;
&#xD;
          3. Known pregnancy and/or lactation, or intent to become pregnant during this study.&#xD;
&#xD;
          4. Doesn't qualify via rEEG analysis due to:&#xD;
&#xD;
               -  Potential physiologic abnormality&#xD;
&#xD;
               -  Low abnormality in comparison to current rEEG database&#xD;
&#xD;
               -  No strong prediction by rEEG analysis for any particular medication class&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles DeBattista, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Kinrys, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven G Potkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Hoffman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>MYnd Analytics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Behavioral Research Specialists</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanti Research and Clinical Trials</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elite Clinical Trials</name>
      <address>
        <city>Wildomar</city>
        <state>California</state>
        <zip>92595</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawaii Clinical Research Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612 / 60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McClean Hospital/Harvard</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478-9106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Medical School - Cambridge Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alpha Behavioral Care, P.A.</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of TX Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>February 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>October 23, 2009</last_update_submitted>
  <last_update_submitted_qc>October 23, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Daniel Hoffman, MD, Chief Medical Officer</name_title>
    <organization>CNS Response, Inc.</organization>
  </responsible_party>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

